Stereotactic Radiation for Growing Brain Metastases
This study is looking at a new way to deliver stereotactic radiation for brain metastases (cancers that have spread to the brain). The goal is to make radiation planning and treatment happen on the same day. This could help ensure the radiation accurately targets the growing or changing brain tumors. Participants will receive linear accelerator-based stereotactic radiation, with some receiving a 0mm planning margin and others a 1mm margin around the tumor. We want to see how many patients have tumor growth beyond the standard 1.0mm planning margin by the time of treatment. You may be able to join if you are an adult with a solid tumor that has spread to the brain, and your brain metastasis is growing at least 1.0mm per week.
- Study design
- This is an interventional study planning to enroll 60 adult participants. Participants will be randomized to receive radiation with either a 0mm or 1mm planning margin.
- What's involved
- You will have radiation planning imaging and treatment on the same day. Repeat scans may be done during treatment if more than 2-3 days pass since the last scans.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at the time of diagnostic MRI to MRI on the first day of treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Ayal A Aizer, MD, MHS · PRINCIPAL_INVESTIGATOR · Dana-Farber/Brigham and Women's Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To assess the percentage of patients that demonstrate tumor beyond the standard planning margin (1.0mm PTV) at the time of stereotactic treatment.Diagnostic MRI to MRI on first day of treatment
Percentage of patients, based on clinical and radiographic assessment, in which the repeat same day/simulation MRI reveals tumor extending beyond a 1.0mm PTV margin of the plan developed on the diagnostic MRI (i.e. the percentage of patients for which the MRI obtained on the same or first day of treatment displays tumor extending 1.0mm beyond the extent of the tumor on the planning MRI).